Value of point-of-care neutrophil gelatinase associated lipocalin in early diagnosis of acute kidney injury in patients with left ventricular systolic dysfunction after coronary angiography

References

• Powell SP, Chawla R, Bottinor W, et al. Race, contrast-induced nephropathy and long-term outcomes after coronary and peripheral angiography and intervention. Cardiovasc Revasc Med. 2018; 19(6S):31–35.
   PubMedGoogle Scholar
• McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008; 51(15):1419–1428.
   PubMed Web of Science ®Google Scholar
• Solomon R. Contrast media nephropathy—how to diagnose and how to prevent? Oxford: Oxford University Press; 2007.
   Google Scholar
• Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med. 2010;4(2):265–280.
   PubMed Web of Science ®Google Scholar
• Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011;57(17):1752–1761.
   PubMed Web of Science ®Google Scholar
• Cowland JB, Sørensen OE, Sehested M, et al. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J Immunol. 2003;171(12):6630–6639.
   PubMed Web of Science ®Google Scholar
• Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14(10):2534–2543.
   PubMed Web of Science ®Google Scholar
• Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, et al. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol. 2006;26(3):287–292.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Bachorzewska-Gajewska H, Poniatowski B, et al. Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Ren Fail. 2009;31(10):910–919.
   PubMed Web of Science ®Google Scholar
• McIlroy DR, Wagener G, Lee HT. Neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery: the effect of baseline renal function on diagnostic performance. Clin J Am Soc Nephrol. 2010;5(2):211–219.
   PubMed Web of Science ®Google Scholar
• Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;100(100):S11–S5.
   Google Scholar
• Yndestad A, Landrø L, Ueland T, et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J. 2009;30(10):1229–1236.
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the european society of cardiology working group on peripheral circulation: endorsed by the association for research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis. 2015;241(2):507–532.
   PubMed Web of Science ®Google Scholar
• van Deursen VM, Damman K, Voors AA, et al. Prognostic value of plasma neutrophil gelatinase–associated lipocalin for mortality in patients with heart failure. Circ Heart Fail. 2014;7(1):35–42.
   PubMed Web of Science ®Google Scholar
• Sahinarslan A, Kocaman SA, Bas D, et al. Plasma neutrophil gelatinase-associated lipocalin levels in acute myocardial infarction and stable coronary artery disease. Coron Artery Dis. 2011;22(5):333–338.
   PubMed Web of Science ®Google Scholar
• Lindberg S, Pedersen SH, Mogelvang R, et al. Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2012;60(4):339–345.
   PubMed Web of Science ®Google Scholar
• Damman K, Masson S, Hillege HL, et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011;32(21):2705–2712.
   PubMed Web of Science ®Google Scholar
• Padhy M, Kaushik S, Girish M, et al. Serum neutrophil gelatinase associated lipocalin (NGAL) and cystatin C as early predictors of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. Clin Chim Acta. 2014; 435:48–52.
   PubMed Web of Science ®Google Scholar
• Liebetrau C, Gaede L, Doerr O, et al. Neutrophil gelatinase-associated lipocalin (NGAL) for the early detection of contrast-induced nephropathy after percutaneous coronary intervention. Scand J Clin Lab Invest. 2014; 74(2):81–88.
   PubMed Web of Science ®Google Scholar
• Briasoulis A, Pala M, Telila T, et al. Statins and contrast-induced nephropathy: a systematic review and Meta-analysis. Curr Pharm Des. 2017; 23(46):7141–7148.
   Web of Science ®Google Scholar
• Liao B, Nian W, Xi A, et al. Evaluation of a diagnostic test of serum neutrophil Gelatinase-Associated lipocalin (NGAL) and urine KIM-1 in Contrast-Induced nephropathy (CIN). Med Sci Monit. 2019;25:565–570.
   PubMed Web of Science ®Google Scholar
• Quintavalle C, Anselmi CV, De Micco F, et al. Neutrophil gelatinase–associated lipocalin and contrast-induced acute kidney injury. Circ Cardiovasc Interv. 2015; 8(9):e002673.
   PubMed Web of Science ®Google Scholar
• Marques FZ, Prestes PR, Byars SG, et al. Experimental and human evidence for lipocalin-2 (neutrophil gelatinase-associated lipocalin [NGAL]) in the development of cardiac hypertrophy and heart failure. J Am Heart Assoc. 2017; 6(6):e005971.
   PubMed Web of Science ®Google Scholar
• Ventoulis I, Mantziari L, Mouratoglou S-A, et al. NGAL and ST2 levels in ambulatory patients with chronic heart failure. Clinical and echocardiographic correlates. Scand Cardiovasc J. 2015;49(4):213–219.
   PubMed Web of Science ®Google Scholar
• Alvelos M, Lourenço P, Dias C, et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol. 2013;165(1):51–55.
   PubMed Web of Science ®Google Scholar
• Haghjooyjavanmard S, Nematbakhsh M, Monajemi A, et al. Von willebrand factor, C-reactive protein, nitric oxide, and vascular endothelial growth factor in a dietary reversal model of hypercholesterolemia in rabbit. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152(1):91–95.
   PubMed Web of Science ®Google Scholar